
Journal of Medicinal Chemistry p. 604 - 608 (1989)
Update date:2022-07-30
Topics:
Thurston
Imakura
Haruna
Li
Liu
Liu
Cheng
Lee
A principal mechanism of action of the clinical antitumor drugs etoposide (1) and teniposide (2) is the inhibition of catalytic activity of type II DNA topoisomerase and concurrent enzyme-mediated production of lethal DNA strand breaks. Substitution of the glycosidic moiety of 1 or 2 by ester and ethers, as well as the esterification and etherification of α-peltatin (4) including its glucosidic ethylidene and thenylidene cyclic acetals (25 and 26), has afforded compounds of much less activity than that of 1. The in vitro cytotoxicity (KB) appears to have no correlation with the inhibitory activity of the human DNA topoisomerase II.
View MoreJiangsu Allyrise Pharmaceutical Co., Ltd.(expird)
Contact:+86-523-86818997
Address:Taizhou,Jiangsu Province,CHINA
Zhengzhou Yuanli Biological Technology Co., Ltd.
Contact:+86-371-67897870/67897895
Address:No. 38, Qingyang Street, Zhengzhou, Henan, China
Contact:0086-22-23410962
Address:17-201, Ningfuli, Shuishanggongyuandong road,Nankai district, Tianjin, China
Sichuan WeiKeqi Biological Technology Co., Ltd.
website:https://www.weikeqi-biotech.com/en
Contact:86-028-81700200
Address:sichuan Chengdu Qingjiang Zhonglu 63号
Nanjing Capatue Chemical Co., Ltd
Contact:+86-25-86371192 +86-025-85720158
Address:No.20 Jiangjun Avenue, Jiangning Economic & Technical Development Zone
Doi:10.1021/jo01091a039
(1959)Doi:10.1021/ja01564a058
(1957)Doi:10.1007/BF03251529
(1956)Doi:10.1039/c39950001139
(1995)Doi:10.1016/j.bmc.2008.01.018
(2008)Doi:10.1021/ol301916t
(2012)